PHASE I/II TRIAL OF BEVACIZUMAB, ERLOTINIB, IMATINIB

贝伐珠单抗、埃洛替尼、伊马替尼的 I/II 期试验

• 批准号: 7605583
• 负责人: Jeffrey A Sosman
• 金额: $ 1.42万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7605583
• 关键词: Bevacizumab/Erlotinib; Computer Retrieval of Information on Scientific Projects Database; Conventional (Clear Cell) Renal Cell Carcinoma; Dose; Drug Combinations; End Point; Funding; Grant; Imatinib; Institution; Patients; Phase; Progression-Free Survivals; Rate; Renal Cell Carcinoma; Research; Research Personnel; Resources; Source; Toxic effect; United States National Institutes of Health; improved; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The combination of bevacizumab, erlotinib and imatinib will be found to substantially improve the response to treatment over bevacizumab and erlotinib alone. " To define tolerable dose levels of bevacizumab, erlotinib, and imatinib when used in combination. " To evaluate the efficacy of this 3-drug combination in the treatment of patients with advanced clear cell renal carcinoma. The primary endpoint in this trial will be the objective response rate. Secondary endpoints will include progression-free survival and overall survival. " To define the overall tolerability and toxicity of this 3-drug combination in advanced renal cell carcinoma.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 将发现贝伐单抗、厄洛替尼和伊马替尼的组合相对于单独的贝伐单抗和厄洛替尼显著改善对治疗的响应。 " 确定贝伐珠单抗、厄洛替尼和伊马替尼联合使用时的耐受剂量水平。 " 目的：评价这3种药物联合治疗晚期肾透明细胞癌的疗效。 本试验的主要终点为客观缓解率。 次要终点将包括无进展生存期和总生存期。 " 确定这3种药物联合治疗晚期肾细胞癌的总体耐受性和毒性。